459814-89-2
459814-89-2
Chemical Structure
AZD-1236
- CAS No.: 459814-89-2
- Formula:C15H19ClN4O5S
- Molecular Weight:402.85
IUPAC Name: (S)-5-(((4-((5-chloropyridin-2-yl)oxy)piperidin-1-yl)sulfonyl)methyl)-5-methylimidazolidine-2,4-dione
InChIKey: SFJFBTPHDHUUPU-OAHLLOKOSA-N
SMILES: C[C@@]1(NC(NC1=O)=O)CS(=O)(N2CCC(CC2)OC3=CC=C(C=N3)Cl)=O
Biological Activity: AZD-1236 is a dual inhibitor of MMP-9 and MMP-12. AZD-1236 selectively inhibits the activities of MMP-9 and MMP-12. AZD-1236 regulates biomarkers, reduces elastin degradation, and decreases lymphocyte levels in sputum and blood. AZD-1236 can be used for research related to chronic obstructive pulmonary disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AZD-1236 | 98.01% | AZD-1236 is a dual inhibitor of MMP-9 and MMP-12. AZD-1236 selectively inhibits the activities of MMP-9 and MMP-12. AZD-1236 regulates biomarkers, reduces elastin degradation, and decreases lymphocyte levels in sputum and blood. AZD-1236 can be used for research related to chronic obstructive pulmonary disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shoari A, et al. Therapeutic potential of inhibitors of gelatinases MMP-2 and MMP-9 for the treatment of breast cancer. The FEBS journal. 2026 Jul;293(13):4014-4042. [Content Brief]
- [2]. Dahl R, et al. Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial. Pulmonary pharmacology & therapeutics. 2012 Apr;25(2):169-77.
- [3]. Magnussen H, et al. Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial. Pulmonary pharmacology & therapeutics. 2011 Oct;24(5):563-70. [Content Brief]
